Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PULSAR ProPhet
NCT06044857Phase 1Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2024
- Primary completion
- Nov 2026
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of gallium ga-68 gozetotide in prostate adenocarcinoma (4 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Evaluation of Target Intra-Prostatic Lesion(s) at 3 months. Started Mar 2024; status: recruiting.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT06044857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06044857.